Apart from making significant cost reductions, Regeneus is in discussions with potential partners about licensing, development and distribution of its allogeneic stem cell products CryoShot and Progenza.
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
